Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Multimodality Therapy before and after Surgery in Patients with Squamous Cell Carcinoma of the Head and Neck

This phase II clinical trial studies how well multimodality therapy works before and after surgery in patients with squamous cell carcinoma of the head and neck. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, nab-paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving carboplatin, nab-paclitaxel, and durvalumab before surgery and using durvalumab with or without radiation therapy and cisplatin after surgery may kill more tumor cells in patients with head and neck cancer.
Head/Neck
Phase II
Adults
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics, Radiotherapy
Carboplatin, Cisplatin, Durvalumab, Nab-Paclitaxel, Radiation
Gibson, Mike
National
Vanderbilt University
07-29-2019
Treatment
VICCHN1890
NCT03174275

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Previously untreated, histologically proven, surgically resectable primary squamous cell carcinoma of the head and neck, stage III or IV (human papilloma virus [HPV] positive or negative non-metastatic disease) according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition; SCCHN of unknown primary is excluded; SCCHN of the oral cavity is allowed; unambiguously squamous Epstein-Barr virus (EBV)-negative nasopharynx cancer will not be excluded nor will unambiguously squamous cancers of the skull base that are clearly surgically resectable and clearly squamous; squamous skin cancer occurring in the head/neck region will not be eligible nor will EBV+ nasopharynx cancer *Note: induction chemotherapy is not considered standard therapy for SCCHN of the oral cavity and participation on this trial will lead to a delay in time to definitive, potentially curative therapy i.e, surgery

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: